We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Efficacy and safety of switching to abacavir/lamivudine (ABC/3TC) plus rilpivirine (RPV) in virologically suppressed HIV-infected patients on HAART.
- Authors
Palacios, R.; Pérez-Hernández, I.; Martínez, M.; Mayorga, M.; González-Domenech, C.; Omar, M.; Olalla, J.; Romero, A.; Romero, J.; Pérez-Camacho, I.; Hernández-Quero, J.; Santos, J.
- Abstract
We analysed the efficacy and safety of switching from a regimen based on nonnucleoside reverse transcriptase inhibitors (NNRTI) or integrase inhibitors (INI) to ABC/3TC + RPV in virologically suppressed HIV-infected patients. This multicentre, retrospective study comprised asymptomatic HIV-infected patients who switched from 2 NRTI + NNRTI or 2 NRTI + INI to ABC/3TC + RPV between February 2013 and December 2013; all had undetectable HIV viral load prior to switching. Efficacy and safety, and changes in lipids and cardiovascular risk (CVR) were analysed at 48 weeks. Of 85 patients (74.1 % men, mean age 49.5 years), 83 (97.6 %) switched from a regimen based on NNRTI (EFV 74, RPV 5, ETV 2, NVP 2), and 45 (53 %) switched from TDF/FTC to ABC/3TC. The main reasons for switching were toxicity (58.8 %) and convenience (29.4 %). At 48 weeks, 78 (91.8 %) patients continued taking the same regimen; efficacy was 88 % by intention to treat, and 96 % by per protocol. Two patients were lost to follow-up and five ceased the new regimen (4 due to adverse effects and 1 virologic failure). Mean CD4 cell counts increased (744 vs. 885 cells/μL; p = 0.0001), and there were mean decreases in fasting total cholesterol (-15.9 mg/dL; p < 0.0001) and LDL-cholesterol (-11.0 mg/dL; p < 0.004), with no changes in HDL-cholesterol, triglycerides, total cholesterol:HDL-cholesterol ratio, and CVR. ABC/3TC + RPV is effective and safe in virologically-suppressed patients on antiretroviral therapy (ART). Forty-eight weeks after switching the lipid profile improved with decreases in total and LDL cholesterol.
- Subjects
ABACAVIR-lamivudine (Drug); DRUG efficacy; RILPIVIRINE; REVERSE transcriptase inhibitors; INTEGRASE inhibitors; THERAPEUTICS
- Publication
European Journal of Clinical Microbiology & Infectious Diseases, 2016, Vol 35, Issue 5, p815
- ISSN
0934-9723
- Publication type
Article
- DOI
10.1007/s10096-016-2602-3